Published in World J Gastroenterol on February 07, 2014
Stem cell therapy in inflammatory bowel disease: A promising therapeutic strategy? World J Stem Cells (2015) 0.93
Mucosally transplanted mesenchymal stem cells stimulate intestinal healing by promoting angiogenesis. J Clin Invest (2015) 0.87
Mesenchymal Stem Cells of Dental Origin-Their Potential for Antiinflammatory and Regenerative Actions in Brain and Gut Damage. Curr Neuropharmacol (2016) 0.81
Dexamethasone and azathioprine promote cytoskeletal changes and affect mesenchymal stem cell migratory behavior. PLoS One (2015) 0.80
The route to pathologies in chronic inflammatory diseases characterized by T helper type 2 immune cells. Clin Exp Immunol (2014) 0.79
Current stage in inflammatory bowel disease: What is next? World J Gastroenterol (2015) 0.78
Feline foamy virus adversely affects feline mesenchymal stem cell culture and expansion: implications for animal model development. Stem Cells Dev (2014) 0.78
Pharmacologic therapy for inflammatory bowel disease refractory to steroids. Clin Exp Gastroenterol (2015) 0.77
Intralymphatic Administration of Adipose Mesenchymal Stem Cells Reduces the Severity of Collagen-Induced Experimental Arthritis. Front Immunol (2017) 0.76
Modern stem cell therapy: approach to disease. Wien Klin Wochenschr (2015) 0.76
Circulating hematopoietic stem cells and putative intestinal stem cells in coeliac disease. J Transl Med (2015) 0.76
Mesenchymal stromal cell-based therapy: Regulatory and translational aspects in gastroenterology. World J Gastroenterol (2016) 0.75
Global hypoxia-ischemia induced inflammation and structural changes in the preterm ovine gut which were not ameliorated by mesenchymal stem cell treatment. Mol Med (2016) 0.75
Biodistribution and Efficacy of Human Adipose-Derived Mesenchymal Stem Cells Following Intranodal Administration in Experimental Colitis. Front Immunol (2017) 0.75
Remission of refractory Crohn's disease after autologous hematopoietic stem cell transplantation. Rev Bras Hematol Hemoter (2015) 0.75
Inflammatory bowel disease: Traditional knowledge holds the seeds for the future. World J Gastrointest Pharmacol Ther (2015) 0.75
Stem cell-based therapies in inflammatory bowel disease: promises and pitfalls. Therap Adv Gastroenterol (2016) 0.75
Lysinibacillus massiliensis Panniculitis Masquerading as Erythema Nodosum: A Case Report. Open Forum Infect Dis (2017) 0.75
Efficacy and safety of autologous hematopoietic stem cell therapy for refractory Crohn's disease: A systematic review and meta-analysis. Medicine (Baltimore) (2017) 0.75
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) 37.55
Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell (2004) 29.32
Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng (2001) 20.65
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet (2007) 13.74
Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet (2004) 11.77
Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet (2010) 9.07
Inflammatory bowel disease. N Engl J Med (2009) 8.62
Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci (2006) 8.09
Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med (2009) 7.53
Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell (2008) 7.47
Immunomodulatory properties of mesenchymal stromal cells. Blood (2007) 6.97
Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol (2002) 6.92
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut (2011) 6.08
Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood (2005) 5.82
Modelling the long QT syndrome with induced pluripotent stem cells. Nature (2011) 5.68
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2011) 5.38
Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation (2006) 5.33
Human mesenchymal stem cells modulate B-cell functions. Blood (2005) 5.12
Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat Genet (2008) 4.96
Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology (2011) 4.88
Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat Immunol (2005) 4.86
Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology (2007) 4.83
Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med (2007) 4.56
Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev (2006) 4.40
The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs (2001) 4.31
Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med (2007) 4.07
Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet (2008) 3.99
Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut (2011) 3.81
Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology (2008) 3.79
Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol (1974) 3.75
Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. Cell Stem Cell (2007) 3.59
Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology (2011) 3.52
Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome. N Engl J Med (2013) 3.39
An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol (2008) 3.30
Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol (2005) 3.12
Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut (2010) 3.09
Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med (2007) 3.02
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96
Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology (2012) 2.95
Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. Am J Pathol (2006) 2.94
Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med (2010) 2.86
Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology (2005) 2.85
Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One (2012) 2.75
Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum (2009) 2.73
Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng (2010) 2.66
A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum (2005) 2.65
Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol (2009) 2.60
Intestinal epithelial cells promote colitis-protective regulatory T-cell differentiation through dendritic cell conditioning. Mucosal Immunol (2009) 2.50
Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology (2008) 2.50
Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood (2002) 2.43
The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology (2011) 2.41
Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J Immunol (2009) 2.37
Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews. Gut (1993) 2.35
Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med (2005) 2.30
2003 report of the intestine transplant registry: a new era has dawned. Ann Surg (2005) 2.27
Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology (2009) 2.26
Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology (2005) 2.25
Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med (2012) 2.19
Investigation of Crohn's disease risk loci in ulcerative colitis further defines their molecular relationship. Gastroenterology (2008) 2.17
Recent insights into the genetics of inflammatory bowel disease. Gastroenterology (2011) 2.12
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut (2009) 2.08
Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology (2012) 2.03
The prognostic power of the NOD2 genotype for complicated Crohn's disease: a meta-analysis. Am J Gastroenterol (2011) 1.93
Course of Crohn's disease after allogeneic marrow transplantation. Gastroenterology (1998) 1.92
Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. Cell Immunol (2009) 1.90
CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells. J Immunol (2004) 1.89
Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT) Bone Marrow Transplant (1997) 1.83
Regulation of homeostasis and inflammation in the intestine. Gastroenterology (2011) 1.82
Mechanisms of mesenchymal stromal cell immunomodulation. Immunol Cell Biol (2012) 1.81
Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood (2010) 1.74
Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant (2009) 1.73
Development of the human gastrointestinal microbiota and insights from high-throughput sequencing. Gastroenterology (2011) 1.70
Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin. Transplantation (2008) 1.70
The genetics of inflammatory bowel disease. Gastroenterology (2007) 1.66
Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica (2009) 1.65
Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scand J Gastroenterol (2000) 1.64
Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc (1999) 1.59
Hospitalisations and surgery in Crohn's disease. Gut (2012) 1.58
Family and twin studies in inflammatory bowel disease. World J Gastroenterol (2006) 1.54
Mesenchymal stem cell-based therapy: a new paradigm in regenerative medicine. J Cell Mol Med (2009) 1.49
Remission of refractory Crohn's disease by high-dose cyclophosphamide and autologous peripheral blood stem cell transplantation. Aliment Pharmacol Ther (2012) 1.47
TSG-6 released from intradermally injected mesenchymal stem cells accelerates wound healing and reduces tissue fibrosis in murine full-thickness skin wounds. J Invest Dermatol (2013) 1.47
Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (2011) 1.46
Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts. Stem Cells Transl Med (2013) 1.44
Remission of Crohn's disease following allogeneic bone marrow transplant for acute leukaemia. Hosp Med (1998) 1.42
Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol (2011) 1.41
Immunomodulatory effects of unselected haematopoietic stem cells autotransplantation in refractory Crohn's disease. Dig Liver Dis (2011) 1.41
Pretreatment with interferon-γ enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells (2011) 1.38
Tolerogenic dendritic cells for autoimmune disease and transplantation. Ann Rheum Dis (2008) 1.36
Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Cell Immunol (2010) 1.36
Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn's disease: a new cell-based therapy. Int J Colorectal Dis (2003) 1.33
Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg (2005) 1.33
East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut (2013) 1.30